Similar findings have also been reported in genetically engineered mice harboring KRAS (Kirsten rat sarcoma viral oncogene homolog) mutation–positive NSCLC co-expressing IL-17A, which resulted in augmentation of neutrophil infiltration and tumor progression, as well as decreased efficacy of PD-1-targeted immunotherapy (129). This evidence concerns the gene KRAS and neoplasm.